3-羟基吡啶-2-硫酮作为新型锌结合基团用于选择性组蛋白去乙酰化酶抑制。
3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.
机构信息
School of Chemistry and Biochemistry, Georgia Institute of Technology , Atlanta, Georgia 30332-0400, United States.
出版信息
J Med Chem. 2013 May 9;56(9):3492-506. doi: 10.1021/jm301769u. Epub 2013 Apr 18.
Abstract
Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date. However, concerns about the pharmacokinetic liabilities of the hydroxamic acid moiety have stimulated research efforts aimed at finding alternative nonhydroxamate ZBGs. We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition. 3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively. Remarkably, 3-HPT gives no inhibition of HDAC 1. Subsequent optimization led to several novel 3HPT-based HDACi that are selective for HDAC 6 and HDAC 8. Furthermore, a subset of these inhibitors induces apoptosis in various cancer cell lines.
摘要
小分子作为锌结合基团（ZBG）的羟肟酸一直是最有效的组蛋白去乙酰化酶抑制剂（HDACi）。然而，人们对羟肟酸部分的药代动力学缺陷的担忧，激发了旨在寻找替代非羟肟酸 ZBG 的研究工作。我们已经确定 3-羟基吡啶-2-硫酮（3-HPT）为新型 ZBG，与 HDAC 抑制兼容。3-HPT 对 HDAC6 和 HDAC8 的抑制作用的 IC50 分别为 681 和 3675 nM。值得注意的是，3-HPT 对 HDAC1 没有抑制作用。随后的优化导致了几种新型基于 3-HPT 的 HDACi，它们对 HDAC6 和 HDAC8 具有选择性。此外，这些抑制剂中的一部分能诱导各种癌细胞系凋亡。
相似文献
1
3-Hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition.3-羟基吡啶-2-硫酮作为新型锌结合基团用于选择性组蛋白去乙酰化酶抑制。
J Med Chem. 2013 May 9;56(9):3492-506. doi: 10.1021/jm301769u. Epub 2013 Apr 18.
2
Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors.基于 3-羟基吡啶-2-硫酮的组蛋白去乙酰化酶抑制剂的合成与构效关系研究。
J Med Chem. 2013 Dec 27;56(24):9969-81. doi: 10.1021/jm401225q. Epub 2013 Dec 12.
3
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.1-羟基吡啶-2-硫酮作为选择性组蛋白去乙酰化酶抑制剂的发现及其在治疗白血病中的潜在应用。
Bioorg Med Chem Lett. 2015 Oct 1;25(19):4320-4. doi: 10.1016/j.bmcl.2015.07.065. Epub 2015 Jul 26.
4
Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.基于吡啶酮的组蛋白去乙酰化酶抑制剂的发现：代谢稳定性的方法。
ChemMedChem. 2013 Feb;8(2):272-9. doi: 10.1002/cmdc.201200529. Epub 2013 Jan 4.
5
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.锌结合基团效应：非羟肟酸伏立诺他类似物的启示。
J Med Chem. 2023 Jun 22;66(12):7698-7729. doi: 10.1021/acs.jmedchem.3c00226. Epub 2023 Jun 5.
6
Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.通过整合定制的药效团特征增强基于药效团的虚拟筛选的灵敏度：以组蛋白去乙酰化酶8为例的研究
J Chem Inf Model. 2015 Apr 27;55(4):861-71. doi: 10.1021/ci500762z. Epub 2015 Mar 16.
7
Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.新型阿魏酸衍生物的开发作为有效的组蛋白去乙酰化酶抑制剂。
Bioorg Med Chem. 2013 Nov 15;21(22):6973-80. doi: 10.1016/j.bmc.2013.09.021. Epub 2013 Sep 19.
8
Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.通过引入杂芳族表面识别基序提高含1,3,4-噻二唑的组蛋白去乙酰化酶（HDAC）抑制剂的抗增殖活性。
Bioorg Med Chem. 2014 Nov 1;22(21):5766-75. doi: 10.1016/j.bmc.2014.09.039. Epub 2014 Sep 28.
9
Inside HDAC with HDAC inhibitors.与 HDAC 抑制剂一起进入 HDAC。
Eur J Med Chem. 2010 Jun;45(6):2095-116. doi: 10.1016/j.ejmech.2010.02.030. Epub 2010 Feb 14.
10
Zinc binding groups for histone deacetylase inhibitors.组蛋白去乙酰化酶抑制剂的锌结合基团。
J Enzyme Inhib Med Chem. 2018 Dec;33(1):714-721. doi: 10.1080/14756366.2017.1417274.
引用本文的文献
1
The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods.组蛋白去乙酰化酶家族：结构特征及联合计算方法的应用
Pharmaceuticals (Basel). 2024 May 10;17(5):620. doi: 10.3390/ph17050620.
2
In the quest for histone deacetylase inhibitors: current trends in the application of multilayered computational methods.在寻找组蛋白去乙酰化酶抑制剂的过程中：多层计算方法应用的当前趋势。
Amino Acids. 2023 Dec;55(12):1709-1726. doi: 10.1007/s00726-023-03297-y. Epub 2023 Jun 27.
3
Hydroxypyrone derivatives in drug discovery: from chelation therapy to rational design of metalloenzyme inhibitors.药物研发中的羟基吡喃酮衍生物：从螯合疗法到金属酶抑制剂的合理设计
RSC Med Chem. 2022 Jul 29;13(10):1127-1149. doi: 10.1039/d2md00175f. eCollection 2022 Oct 19.
4
Uracil as a Zn-Binding Bioisostere of the Allergic Benzenesulfonamide in the Design of Quinoline-Uracil Hybrids as Anticancer Carbonic Anhydrase Inhibitors.在喹啉-尿嘧啶杂化物作为抗癌碳酸酐酶抑制剂的设计中，尿嘧啶作为过敏性苯磺酰胺的锌结合生物电子等排体。
Pharmaceuticals (Basel). 2022 Apr 19;15(5):494. doi: 10.3390/ph15050494.
5
Evaluation of histone deacetylase inhibitor substituted zinc and indium phthalocyanines for chemo- and photodynamic therapy.用于化学疗法和光动力疗法的组蛋白脱乙酰酶抑制剂取代的锌酞菁和铟酞菁的评估
RSC Adv. 2021 Oct 28;11(55):34963-34978. doi: 10.1039/d1ra05404j. eCollection 2021 Oct 25.
6
Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges.炎症、纤维化与癌症：机制、治疗选择及挑战
Cancers (Basel). 2022 Jan 22;14(3):552. doi: 10.3390/cancers14030552.
7
High Antiproliferative Activity of Hydroxythiopyridones over Hydroxypyridones and Their Organoruthenium Complexes.羟基硫代吡啶酮相对于羟基吡啶酮及其有机钌配合物具有高抗增殖活性。
Biomedicines. 2021 Jan 27;9(2):123. doi: 10.3390/biomedicines9020123.
8
A Translational Study of a Silicon Phthalocyanine Substituted with a Histone Deacetylase Inhibitor for Photodynamic Therapy.一种用组蛋白去乙酰化酶抑制剂取代的硅酞菁用于光动力疗法的转化研究。
ACS Omega. 2020 Oct 2;5(40):25854-25867. doi: 10.1021/acsomega.0c03180. eCollection 2020 Oct 13.
9
HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?HDAC6——慢性髓性白血病的一个新兴靶点？
Cancers (Basel). 2020 Jan 29;12(2):318. doi: 10.3390/cancers12020318.
10
Deferiprone: Pan-selective Histone Lysine Demethylase Inhibition Activity and Structure Activity Relationship Study.地拉罗司：泛选择性组蛋白赖氨酸去甲基酶抑制活性及构效关系研究。
Sci Rep. 2019 Mar 18;9(1):4802. doi: 10.1038/s41598-019-39214-1.
本文引用的文献
1
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.靶向癌症治疗：给予组蛋白去乙酰化酶抑制剂成功所需的一切。
Future Med Chem. 2012 Mar;4(4):505-24. doi: 10.4155/fmc.12.3.
2
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.新型双功能抑制剂双重靶向组蛋白去乙酰化酶和拓扑异构酶 II。
J Med Chem. 2012 Feb 23;55(4):1465-77. doi: 10.1021/jm200799p. Epub 2012 Feb 13.
3
Molecular basis for the actions of Hsp90 inhibitors and cancer therapy.Hsp90 抑制剂作用机制与癌症治疗。
J Antibiot (Tokyo). 2011 Sep;64(9):635-44. doi: 10.1038/ja.2011.60. Epub 2011 Aug 3.
4
High-throughput screening of small molecule libraries using SAMDI mass spectrometry.高通量筛选小分子文库的 SAMDI 质谱法。
ACS Comb Sci. 2011 Jul 11;13(4):347-50. doi: 10.1021/co2000373. Epub 2011 Jun 3.
5
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.选择性抑制组蛋白去乙酰化酶 6（HDAC6）可诱导 DNA 损伤，并使转化细胞对抗癌药物敏感。
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20003-8. doi: 10.1073/pnas.1013754107. Epub 2010 Oct 29.
6
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.组蛋白去乙酰化酶抑制减轻自发性高血压大鼠的炎症、肥大和高血压反应。
Hypertension. 2010 Sep;56(3):437-44. doi: 10.1161/HYPERTENSIONAHA.110.154567. Epub 2010 Aug 2.
7
Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.来源于三环酮内酯骨架的非肽类大环组蛋白去乙酰化酶抑制剂。
J Med Chem. 2010 Aug 26;53(16):6100-11. doi: 10.1021/jm100507q.
8
Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.合理设计和简单化学方法产生了一种优越的、具有神经保护作用的 HDAC6 抑制剂，即 tubastatin A。
J Am Chem Soc. 2010 Aug 11;132(31):10842-6. doi: 10.1021/ja102758v.
9
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.含三唑连接帽基团的组蛋白去乙酰化酶抑制剂的抗疟和抗利什曼原虫活性。
Bioorg Med Chem. 2010 Jan 1;18(1):415-25. doi: 10.1016/j.bmc.2009.10.042. Epub 2009 Oct 27.
10
Multiple roles of HDAC inhibition in neurodegenerative conditions.组蛋白去乙酰化酶抑制在神经退行性疾病中的多种作用。
Trends Neurosci. 2009 Nov;32(11):591-601. doi: 10.1016/j.tins.2009.06.002. Epub 2009 Sep 21.
Zotero 插件